Microalbuminuria in Primary Hypertension: a Guide to Optimal Patient Management?

Overview

Journal J Nephrol

Publisher Springer

Specialty Nephrology

Date 2016 Jul 16

PMID 27417557

Citations 9

Authors

Francesca Viazzi

Francesca Cappadona

Roberto Pontremoli

Affiliations

Soon will be listed here.

Abstract

Accurate assessment of the global risk profile is considered a prerequisite for the optimal management of hypertensive patients. In particular, the evaluation of subclinical organ damage, namely left ventricular hypertrophy, peripheral atherosclerosis and renal function, plays a key role in optimizing therapeutic targets and strategy in individual patients. Urine albumin excretion is a low-cost, easy-to-use test and a powerful predictor of cardiovascular diseases. The search for albuminuria has, therefore, become routine in the evaluation of hypertensive patients. Moreover, albuminuria has been shown to be associated with early signs of extra-renal organ damage such as left ventricular hypertrophy, and carotid atherosclerosis. Under effective antihypertensive treatment, changes in subclinical organ damage over time, especially regression of left ventricular hypertrophy, are paralleled by modification of risk status and may serve as intermediate endpoints for treatment. More recently, changes in albuminuria have also been proposed to reflect changes in the risk of cardiovascular events. If this is confirmed by large well-designed studies, microalbuminuria may not simply be regarded as a risk predictor but become itself an independent target for treatment.

Citing Articles

Hypertension management in primary health care: a survey in eight regions of Sweden.

Hellgren M, Wennberg P, Hedin K, Jansson S, Nilsson S, Nilsson G Scand J Prim Health Care. 2023; 41(3):343-350.

PMID: 37561134 PMC: 10478603. DOI: 10.1080/02813432.2023.2242711.

Decreased Urinary Levels of as Non-Invasive Biomarker of Early Renal Damage in Hypertension.

Martinez-Arroyo O, Ortega A, Galera M, Solaz E, Martinez-Hervas S, Redon J Int J Mol Sci. 2020; 21(17).

PMID: 32887498 PMC: 7503821. DOI: 10.3390/ijms21176390.

Cross-Sectional Relationship between Carotid-Femoral Pulse Wave Velocity and Biomarkers in Vascular-Related Diseases.

Liu J, Wang K, Liu H, Zhao H, Huang W, Zhao N Int J Hypertens. 2020; 2020:6578731.

PMID: 32537254 PMC: 7267861. DOI: 10.1155/2020/6578731.

Bidirectional and Temporal Association Between Hypertension and Microalbuminuria: A Longitudinal Study in Chinese Adults.

Zhang M, Jiang Y, Zhang Q, Chen Y, He Y, Lin Y J Am Heart Assoc. 2018; 7(22):e010723.

PMID: 30571489 PMC: 6404448. DOI: 10.1161/JAHA.118.010723.

Genome-wide association studies of albuminuria: towards genetic stratification in diabetes?.

Pattaro C J Nephrol. 2017; 31(4):475-487.

PMID: 28918587 DOI: 10.1007/s40620-017-0437-3.

References

Pedrinelli R, DellOmo G, Di Bello V, Pontremoli R, Mariani M . Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens. 2002; 16(2):79-89. DOI: 10.1038/sj.jhh.1001316. View

Viazzi F, Leoncini G, Pontremoli R . Global cardiovascular risk assessment in the management of primary hypertension: the role of the kidney. Int J Hypertens. 2013; 2013:542646. PMC: 3745834. DOI: 10.1155/2013/542646. View

Devereux R, De Simone G, Roman M . Relations of left ventricular geometry and function to prognosis in hypertension. Adv Exp Med Biol. 1997; 432:1-12. DOI: 10.1007/978-1-4615-5385-4_1. View

Klingbeil A, Schneider M, Martus P, Messerli F, Schmieder R . A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003; 115(1):41-6. DOI: 10.1016/s0002-9343(03)00158-x. View

Tanaka F, Komi R, Makita S, Onoda T, Tanno K, Ohsawa M . Low-grade albuminuria and incidence of cardiovascular disease and all-cause mortality in nondiabetic and normotensive individuals. J Hypertens. 2016; 34(3):506-12. DOI: 10.1097/HJH.0000000000000809. View

Alberti K, Zimmet P . Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15(7):539-53. DOI: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S. View

Muiesan M, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E . Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens. 1995; 13(10):1091-5. DOI: 10.1097/00004872-199510000-00003. View

Ratto E, Viazzi F, Bonino B, Gonnella A, Garneri D, Parodi E . Left ventricular dilatation and subclinical renal damage in primary hypertension. J Hypertens. 2014; 33(3):605-11. DOI: 10.1097/HJH.0000000000000430. View

Devereux R, Alderman M . Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation. 1993; 88(4 Pt 1):1444-55. DOI: 10.1161/01.cir.88.4.1444. View

10.

Pierdomenico S, Lapenna D, Cuccurullo F . Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension. Am J Hypertens. 2008; 21(4):464-70. DOI: 10.1038/ajh.2008.2. View

11.

Viazzi F, Leoncini G, Conti N, Tomolillo C, Giachero G, Vercelli M . Combined effect of albuminuria and estimated glomerular filtration rate on cardiovascular events and all-cause mortality in uncomplicated hypertensive patients. J Hypertens. 2010; 28(4):848-55. DOI: 10.1097/HJH.0b013e328336ed09. View

12.

Hallan S, Matsushita K, Sang Y, Mahmoodi B, Black C, Ishani A . Age and association of kidney measures with mortality and end-stage renal disease. JAMA. 2012; 308(22):2349-60. PMC: 3936348. DOI: 10.1001/jama.2012.16817. View

13.

Viazzi F, Leoncini G, Ratto E, Vaccaro V, Tomolillo C, Falqui V . Microalbuminuria, blood pressure load, and systemic vascular permeability in primary hypertension. Am J Hypertens. 2006; 19(11):1183-9. DOI: 10.1016/j.amjhyper.2006.04.012. View

14.

Pontremoli R, Sofia A, Ravera M, Nicolella C, Viazzi F, Tirotta A . Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC Study. Microalbuminuria: A Genoa Investigation on Complications. Hypertension. 1997; 30(5):1135-43. DOI: 10.1161/01.hyp.30.5.1135. View

15.

Liu C, Chen H, Liu C, Fu C, Zhang H, Yang H . Combined application of eGFR and albuminuria for the precise diagnosis of stage 2 and 3a CKD in the elderly. J Nephrol. 2014; 27(3):289-97. DOI: 10.1007/s40620-013-0011-6. View

16.

Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E . Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015; 3(7):514-25. PMC: 4594193. DOI: 10.1016/S2213-8587(15)00040-6. View

17.

Pontremoli R, Leoncini G, Viazzi F, Ratto E, Vaccaro V, Falqui V . Evaluation of subclinical organ damage for risk assessment and treatment in the hypertensive patient: role of microalbuminuria. J Am Soc Nephrol. 2006; 17(4 Suppl 2):S112-4. DOI: 10.1681/ASN.2005121327. View

18.

Pedrinelli R, Giampietro O, Carmassi F, Melillo E, DellOmo G, Catapano G . Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet. 1994; 344(8914):14-8. DOI: 10.1016/s0140-6736(94)91047-2. View

19.

Ravera M, Ratto E, Vettoretti S, Viazzi F, Leoncini G, Parodi D . Microalbuminuria and subclinical cerebrovascular damage in essential hypertension. J Nephrol. 2002; 15(5):519-24. View

20.

Schmieder R, Mann J, Schumacher H, Gao P, Mancia G, Weber M . Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol. 2011; 22(7):1353-64. PMC: 3137583. DOI: 10.1681/ASN.2010091001. View